Key result
Intracoronary streptokinase linked to ~76% more hemorrhagic complications requiring blood replacement versus IV streptokinase.
Why the study?
Does intracoronary versus intravenous streptokinase differentially affect coagulation and fibrinolytic parameters in patients with evolving acute myocardial infarction?
Cohort (n=45)
Does intracoronary versus intravenous streptokinase differentially affect coagulation and fibrinolytic parameters in patients with evolving acute myocardial infarction?
Both intracoronary and intravenous streptokinase produce a similar generalized fibrinolytic state in acute myocardial infarction, though hemorrhagic complications may differ.
Answers are grounded in this paper and cite their sources.
May heighten transfusion-requiring hemorrhage with intracoronary streptokinase; leaves open differential effects on coagulation parameters in acute MI.
Twenty-two patients were infused with 240,000 units streptokinase during a 60-minute period into the ostium of the infarct-related coronary artery (IC), and 23 patients were infused with 1,500,000 units streptokinase intravenously (IV) over 45 minutes; all infusions occurred within 12 hours of the patients' onset of chest pain. Thereafter, heparin was infused for 10 days. Serial coagulation and fibrinolytic parameters were studied over 46 to 72 hours after the streptokinase infusion. A generalized fibrinolytic state was produced in both groups as evidenced by a fall in fibrinogen and plasminogen levels, prolongation of thrombin and reptilase clotting times, a rise in fibrinogen degradation products, and a shortening of the euglobulin lysis time. Recovery to preinfusion levels was similar in both groups of patients. Hemorrhagic complications requiring blood replacement occurred in 7/23 (30%) treated IC, and 4/23 (17%) in the IV group.
No takes yet. Share an insight, caveat, or question.
Lurie et al. (1990) conducted a cohort in Acute Myocardial Infarction (n=45). Intracoronary streptokinase vs. Intravenous streptokinase was evaluated on Hemorrhagic complications requiring blood replacement. Intracoronary streptokinase resulted in hemorrhagic complications requiring blood replacement in 30% of patients compared to 17% with intravenous streptokinase.
Synapse has enriched 10 related papers. Consider them for comparative context: